Amylyx's avexitide cuts hypoglycemia events 55% in Phase 3 trial

August 18, 2026 7:00 AM

Amylyx Pharmaceuticals (Nasdaq: AMLX) reported positive topline results from its Phase 3 LUCIDITY clinical trial evaluating avexitide, an investigational GLP-1 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found